Seres Therapeutics (MCRB) Misses Q2 EPS by 218c

Seres Therapeutics (NASDAQ: MCRB) reported Q2 EPS of ($2.27), $2.18 worse than the analyst estimate of ($0.09).

For earnings history and earnings-related data on Seres Therapeutics (MCRB) click here.

You May Also Be Interested In

• Eli Lilly: Q2 2026 IPR&D charge estimated at $3.02 per share on GAAP and non-GAAP basis
• Dollar Tree upgraded on earnings upside potential despite ongoing traffic woes
• Rambus launches DDR5 9600 server RDIMM chipset for AI workloads